| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917833 | Radiotherapy and Oncology | 2016 | 5 Pages |
Abstract
With the changed dosing schedule, this regimen was very well tolerated. The tumor pCR and downstaging rates are encouraging and support further clinical investigation of this regimen.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Richard Kim, Gopi Kesaria Prithviraj, Ravi Shridhar, Sarah E. Hoffe, Kun Jiang, Xiuhua Zhao, Dung-Tsa Chen, Khaldoun Almhanna, Jonathan Strosberg, Tiffany Campos, David Shibata,